/Investor DB

Novalis LifeSciences — 2021 Investments

2 investments dated 2021 · listed companies and verified rows first · show all

Vizgenvizgen.comin𝕏Mar 2021SEC filingmedium confidence

Vizgen develops spatial profiling instruments and reagents for high-throughput analysis of gene expression and protein distribution in tissue samples.

AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US

George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inRobert Carson(Executive Officer, Director)Terry Lo(Director)inSeth Benson(Executive Officer)inSimona Levi(Executive Officer)in

Board seatMarijn Dekkers· per SEC Form D · $37M raise · filed Apr 2021

Co-investorsARCH Venture PartnersM VenturesNorthpond VenturesIllumina Ventures

ロゴマーク:AIRNAairna.cominSep 2021

AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.

AI & Machine LearningBiotechDeep TechHealthtechStanford, US

Thorsten Stafforst(Chairman of the Board of Directors)inKris ElveruminTodd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in

BoardRodger Novak(Chair)in

Co-investors+ND CapitalARCH Venture PartnersForbionVenrockFast Track InitiativeNextech Invest+2 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.